Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Ralf‐Dieter Hofheinz(University of Mannheim), Stephan Probst(Klinikum Bielefeld), Georg Martin Haag(Heidelberg University), Gunnar Folprecht, E. Jaeger(Krankenhaus Nordwest), Hans‐Georg Kopp(Robert Bosch Hospital), Martin Schüler(German Cancer Research Center), Nicole Prasnikar(Asklepios Klinik Barmbek), Jörg Trojan(Goethe University Frankfurt), Kim Barbara Luley(University Hospital Schleswig-Holstein), Harald Schmalenberg(Heidelberg University), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Michael Koenigsmann, Claudia Pauligk(Goethe University Frankfurt), Wolfgang Fischbach(Klinikum Aschaffenburg), Nils Homann(Fraunhofer Project Centre Wolfsburg)
Cited by 239
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k